# Immuron (IMRN) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/IMRN
## Company Profile
- Ticker: IMRN
- Exchange: NASDAQ
- Sector: Biopharma
- Location: Australia and listed in the U
- Tags: Immunotherapy
## Stock Data
- Close: 1.11 USD
- Market cap: 10779568.8 USD
- Last updated: 2026-10-08
## Business Overview
Immuron is a biotechnology company focused on orally delivered immunotherapies and gastrointestinal health. Its business is centered on leveraging immune biology for GI and infectious-related uses.
## Why The Stock Is Moving

As of Oct 8, 2026, IMRN closed up 1.83% at $1.11. No new same-company headline was identified in the current news window.

## Geographic Base

Immuron is headquartered in Australia and listed in the U.S. market. It sits in small-cap biotechnology with a GI and immunology focus.

## Business Model

The company depends on clinical and commercial progress, plus capital efficiency. Investors usually watch data, product uptake, and strategic development.

## Landscape Position

Immuron occupies a niche GI-immunology position within biotech. The stock is sensitive to whether oral immune biology can translate into a meaningful market.

## Future Catalysts

- Immuron’s catalysts are its oral immunotherapy and infectious-disease products, plus any commercialization update that shows the platform can keep gaining traction. The company moves on recurring demand and product execution.

## Recent News
- 2026-09-04 10:00 EST — [Immuron to launch PROIBS® in the United States](https://biopharmsignal.com/news/IMRN/immuron-to-launch-proibs-in-the-united-states-e7e76d39) — Source: Immuron
- 2026-08-28 10:00 EST — [Immuron Reports FY26 Preliminary Results](https://biopharmsignal.com/news/IMRN/immuron-reports-fy26-preliminary-results-3cbe2d6e) — Source: Immuron
- 2026-07-20 10:00 EST — [Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar](https://biopharmsignal.com/news/IMRN/immuron-ceo-steven-lydeamore-presentation-at-kalkine-media-webinar-ebc4e4b7) — Source: Immuron
- 2026-07-16 10:00 EST — [Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year](https://biopharmsignal.com/news/IMRN/immuron-fy26-sales-four-consecutive-quarters-of-growth-over-prior-year-6f03cdb9) — Source: Immuron
- 2026-07-06 10:00 EST — [Immuron Advances IMM-529 (Clostridioides difficile infection) Partnering Strategy](https://biopharmsignal.com/news/IMRN/immuron-advances-imm-529-clostridioides-difficile-infection-partnering-strategy-00549010) — Source: Immuron